Figure 5. SCD1 pharmacological inhibition decreases 018z cells engraftment in the CNS.

In vitro proliferation of “SCD1-high”, “SCD1-low” and matching control (CTL) 018z cells after seeding 0.5x10⁶ cells/well for 96 hours in medium supplemented with 10% lipidated (A-B) or delipidated (C-D) FBS treated with 1μM of the SCD1 inhibitor SW203668 or vehicle (DMSO).The dotted line represents the initial number of cells plated at T₀. p=two-way ANOVA. (D) GFP⁺mCherry⁺FFLuc⁺ 018z cells were injected intravenously to NSG mice and treated from day 1 to day 10 with the SCD1 inhibitor SW203668 or vehicle (n=5 group). Representative bioluminescence of the tumor load at the time of sacrifice in three different pairs of mice, top: vehicle treated mice; bottom: drug treated mice. Decrease in the tumor load is clear in the spine and the skull area (CNS – marked with white box). Total amount of leukemic cells in CNS (E) and BM (F) of NSG mice xenografted with human GFP⁺mCherry⁺FFLuc⁺ 018z and treated with SW203668 for 10 days at the time of sacrifice. The backbone vector for SCD1 overexpression was used as control vector for SCD1-high and the scramble vector was used as control for SCD1-low. BM – bone marrow. p=Student’s t-test.